Pharmaceutical priority setting and the use of health economic evaluations: A systematic literature review

Value in Health

Volumn 14, Issue 4, 2011, Pages 587-599

  Erntoft, Sandra ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Economic evaluation; Literature review; Pharmaceutical; Priority setting

Indexed keywords

DRUG;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; EMPIRICAL RESEARCH; HUMAN; MEDICAL DECISION MAKING; MESH HEADING; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; SWEDEN; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES;

EID: 79960013935     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.036     Document Type: Review

References (44)

1. Van Velden ME, Severens JL, Novak A. Economic evaluations of health programmes and decision making: the influence of economic evaluations on different health-care decision-making levels. Pharmacoeconomics 2005;23:1075-82. (Pubitemid 41633400)
2. Neumann P, Fang C-H, Cohen JT. 30 years of pharmaceutical costutility analyses. Growth, diversity and methodological improvement. Pharmacoeconomics 2009;27:861-72.
3. Manca A. Economic evaluation of medical devices and drugs-same or different? Value Health 2009;12:401.
4. Coyle D. Increasing the Impact of Economic Evaluations in Health-Care Decision Making. Discussion Paper 108: Centre for Health Economics, University of York, Health Economics Consortium, 1993.
5. Drummond M, Cooke J, Walley T. Economic Evaluation in Health Care Decision Making: Evidence from the UK. Discussion Paper 148, Centre for Health Economics, University of York, Health Economics Consortium, 1996.
6. McDonald R. Using Health Economics in Health Services. Rationing Rationally? Buckingham: Open University Press, 2002.
7. Williams IP, Bryan S. The use of health economic evaluations in NHS decision making. A review and empirical investigation. Health Technology Assessment NHS R&D HTA Programme. Health Technology Assessment 2008;12:1-196.
8. Eddama O, Coast J. A systematic review of the use of economic evaluation in local decision-making. Health Policy 2008;86:129-41.
9. CDR. Centre for Reviews and Dissemination. Systematic Reviews. CDR guidance for undertaking reviews in health care. 2009. Available from: www.york.ac.uk/inst/crd/pdf/Systematic-Reviews.pdf. [Accessed October 2, 2009].
10. Späth HM. L'utilitasion del'information economique dans le secteur de la santé: le choix des medicaments a inclure dans les livret thérapeutiques hospitaliers. J Economie Med 2000;18:147-61.
11. Suh DC, Okpara IRN, Agnese WB, Toscani M. Application of pharmacoeconomics to formulary decision making in managed care organizations. Am J Manag Care 2002;8:161-9. (Pubitemid 38351931)
12. Walkom E, Robertson J, Newby D, Pillay T. The role of pharmacoeconomics in formulary decision making. Considerations for hospital and managed care pharmacy and therapeutics committees. Formulary 2006;41:374-86.
13. Vourenkoski L, Toivaninen H, Hemminki E. Decision-making in priority setting for medicines - a review of empirical studies. Health Policy 2008;86:1-9. (Pubitemid 351296302)
14. Martin DK, Hollenberg D, MacRae S, et al. Priority setting in a hospital drug formulary: a qualitative case study and evaluation. Health Policy 2003;66:295-303. (Pubitemid 37433960)
15. Williams IP, Bryan S. Cost-effectiveness analysis and formulary decision making in England: findings from research. Soc Sci Med 2007;65:2116-29. (Pubitemid 47593038)
16. Chen LC, Ashcroft DM, Elliott RA. Do economic evaluations have a role in decision-making in Medicine Management Committees? A qualitative study. Pharm World Science 2007;29:661-70. (Pubitemid 47594176)
17. Erntoft, S. The use of health economic evaluations in pharmaceutical priority setting - the case of Sweden. Doctoral dissertation. Lund Studies in Economics and Management 116. Lund, Sweden: Lund Business Press, 2010.
18. Brody B, Wray N, Bame S, et al. The impact of economic considerations on clinical decisionmaking. The case of thrombolytic therapy. Med Care 1991;29:899-910.
19. Erkan D, Yazici Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Rheum 2002;47:285-90. (Pubitemid 34627697)
20. Kangis P, van der Geer L. Pharmaco-economic information and its effect on prescriptions. J Manag Med 1996;10:66-74.
21. Jansson S, Anell A. The impact of decentralised drug-budgets in Sweden - a survey of physicians' attitudes towards cost and cost-effectiveness. Health Policy 2006;76:299-311.
22. Walley T, Baron S, Cooke J, Drummond M. Economic evaluations of drug therapy: attitudes of primary care prescribing advisors in Great Britain. Health Policy 1997;41:961-72.
23. Evans C, Dukes E, Crawford B. The role of pharmacoeconomic information in the formulary decision-making process. J Manag Care Pharm 2000;6:108-21.
24. Grabowski H, Mullins CD. Pharmacy benefits management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med 1997;45:535-44. (Pubitemid 27353075)
25. Lyles A, Luce RB, Rentz A. Managed care pharmacy, socioeconomic assessments and drug adoption decisions. Soc Sci Med 1997;45:511-21. (Pubitemid 27353073)
26. Martin DK, Pater JL, Singer PA. Priority-setting decisions for new cancer drugs: a qualitative case study. Lancet 2001;358:1676-81. (Pubitemid 33124325)
27. Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making 2008;28;713-22.
28. Anell A, Svarvar P. Pharmacoeconomics and clinical practice guidelines. A survey of attitudes in Swedish formulary committees. Pharmacoeconomics 2000;17:175-85. (Pubitemid 30148814)
29. Kulsomboon V, Palumbo F, Mullins C. Criteria to request pharmacoeconomic data and data sources for hospital formulary decisions. Drug Inf J 2001;35:231-40. (Pubitemid 32198574)
30. Odedina FT, Sullivan J, Nash R, Clemmons CD. Use of pharmacoeconomic data in making hospital formulary decisions. Am J Health Syst Res 2002;59:1441-4.
31. Jenkings KN, Barber N. What constitutes evidence in hospital new drug decision making? Soc Sci Med 2004;58:1757-66. (Pubitemid 38281141)
32. Williams IP, Bryan S, McIver S. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the national institute for health and clinical excellence approach. J Health Serv Res Policy 2007;12:73-9. (Pubitemid 46733207)
33. Sloan FA, Whetten-Goldstein K, Wilson A. Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis. Soc Sci Med 1997;45:523-33. (Pubitemid 27353074)
34. Späth HM, Charavel M, Morelle M, Carrere MO. A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey. Pharm World Sci 2003;25:269-75. (Pubitemid 37498932)
35. Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Soc Sci Med 1997;45:563-81. (Pubitemid 27353078)
36. Bryan S, Williams I, McInver S. Seeing the nice side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. Health Econ 2007;16:179-93. (Pubitemid 46206612)
37. Anell A, Persson U. Reimbursement and clinical guidance for pharmaceuticals in Sweden. Do health-economic evaluations support decision making? Eur J Health Econ 2005;50:274-9. (Pubitemid 41643700)
38. Jansson S. Implementing accountability for reasonableness - the case of pharmaceutical reimbursement in Sweden. Health Econ Policy Law 2007;2:153-71.
39. Anell A. Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees. Eur J Health Econ 2004;5:28-35. (Pubitemid 38315894)
40. Haslé-Pham E, Arnould B, Späth H-M, et al. Role of clinical, patient reported outcome and medico-economic studies in the public hospital drug formulary decision-making process: results of a European survey. Health Policy 2005;71:205-12. (Pubitemid 39647631)
41. Cox E, Motheral B, Griffis D. Relevance of pharmacoeconomics and health outcomes information to health care decision makers in the United States. Value Health 2000;3:162.
42. Grizzle A, Motheral B, Garrity B, et al. A qualitative assessment of managed care decision maker's views and use of pharmacoeconomic information. Value Health 2000;3:162-3.
43. West R, Borden E, Collet J-P, et al. "Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement. Can J Public Health 2002;93:421-5. (Pubitemid 35414598)
44. Neumann PJ. Using Cost-Effectiveness Analysis to Improve Health Care. Opportunities and Barriers. New York: Oxford University Press, 2005.